None of Avon’s Operations Outside the U.S. are Part of Legal Proceedings Business as Usual Across International Markets as Brand Advances Strategic Initiatives NEW YORK, Aug. 12, 2024 /PRNewswire/ — Avon Products, Inc. (“API”), a U.S.-based non-operational holding company of the Avon…
Month: August 2024
None of Avon’s Operations Outside the U.S. are Part of Legal Proceedings Business as Usual Across International Markets as Brand Advances Strategic Initiatives NEW YORK, Aug. 12, 2024 /PRNewswire/ — Avon Products, Inc. (“API”), a U.S.-based non-operational holding company of the Avon…
HOUSTON, Aug. 12, 2024 /PRNewswire/ — Western Midstream Partners, LP (NYSE: WES) (“WES”) announced today the pricing of the previously announced underwritten secondary public offering of 19,000,000 common units representing limited partner interests in WES (“Common Units”) by affiliates…
HOUSTON, Aug. 12, 2024 /PRNewswire/ — Western Midstream Partners, LP (NYSE: WES) (“WES”) announced today the pricing of the previously announced underwritten secondary public offering of 19,000,000 common units representing limited partner interests in WES (“Common Units”) by affiliates…
PLATTSBURGH, N.Y., Aug. 12, 2024 /PRNewswire/ — Entering Championship Monday at the Tackle Warehouse Bassmaster Elite at Lake Champlain, Day 3 leader Ed Loughran III thought he needed another 20-pound bag to win his first blue trophy. So, when he finished with a 16-pound, 14-ounce limit…
PLATTSBURGH, N.Y., Aug. 12, 2024 /PRNewswire/ — Entering Championship Monday at the Tackle Warehouse Bassmaster Elite at Lake Champlain, Day 3 leader Ed Loughran III thought he needed another 20-pound bag to win his first blue trophy. So, when he finished with a 16-pound, 14-ounce limit…
Research Confirms Effective Control of Large Liver Cancer, Doubling Survival Time Published in the International Journal of Radiation Oncology TAOYUAN, Aug. 12, 2024 /PRNewswire/ — With cancer incidence on the rise, proton therapy has emerged as one of the most powerful tools in cancer…
Research Confirms Effective Control of Large Liver Cancer, Doubling Survival Time Published in the International Journal of Radiation Oncology TAOYUAN, Aug. 12, 2024 /PRNewswire/ — With cancer incidence on the rise, proton therapy has emerged as one of the most powerful tools in cancer…
SINGAPORE, Aug. 12, 2024 /PRNewswire/ — Biosyngen is proud to announce that the U.S. Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with a pivotal Phase lI clinical trial. This marks the first cell therapy to enter Phase lI…
SINGAPORE, Aug. 12, 2024 /PRNewswire/ — Biosyngen is proud to announce that the U.S. Food and Drug Administration (FDA) has approved its BRG01, an EBV-specific CAR-T cell therapy, to proceed with a pivotal Phase lI clinical trial. This marks the first cell therapy to enter Phase lI…